New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 30, 2014
05:33 EDTQGEN, LLYQIAGEN, Eli Lilly collaborate to co-develop companion cancer diagnostics
QIAGEN N.V. (QGEN) announced a collaboration with Eli Lilly (LLY) to co-develop universal and modular assay panels for the simultaneous analysis of DNA and RNA biomarkers targeting multiple cellular pathways involved in common cancer types. The agreement includes the development of tests that will be based on QIAGEN's multi-modal, multi-analyte Modaplex analysis platform, which can process multiple sample types and biomarkers in a single test.
News For QGEN;LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 2, 2014
10:00 EDTLLYZimmer antitrust probe extended, Lilly/Novartis deal cleared by EU, Reuters says
Subscribe for More Information
08:35 EDTLLYEli Lilly to discontinue Tabalumab development based on Phase 3 lupus results
Eli Lilly will discontinue development of tabalumab­, being studied for the treatment of systemic lupus erythematosus, commonly known as lupus, due to insufficient efficacy in two pivotal Phase 3 trials. The decision was not based on safety concerns. The decision to discontinue development of tabalumab for lupus is expected to result in a Q3 charge to research and development expense of up to $75M pretax, or approximately 4c-5c per share after-tax.
September 30, 2014
16:39 EDTLLYCMS discloses drug makers' payments to doctors, WSJ says
Subscribe for More Information
07:30 EDTQGEN, LLYSachs Associates to hold a conference
14th Annual Biotech in Europe Forum for Global Partnering and Investment to be held in Basel, Switzerland on September 30-October 1.
September 23, 2014
09:00 EDTLLYBofa/Merill special situations team to hold an analyst/industry conference call
Subscribe for More Information
September 22, 2014
08:38 EDTQGENQIAGEN to begin new buyback program after completing prior one
QIAGEN informed that it will commence the launch of a share repurchase program after completing its prior program on September 17. Reference Link
07:21 EDTLLYEBD Group to hold a conference
Subscribe for More Information
September 18, 2014
15:57 EDTLLYFDA approves Trulicity with boxed warning, post-marketing study requirements
Subscribe for More Information
15:55 EDTLLYFDA approves Eli Lilly type 2 diabetes drug
Subscribe for More Information
11:15 EDTLLYRepros sinks after panel backs tests for testosterone therapies
Subscribe for More Information
08:12 EDTLLYEli Lilly's Cyramza for gastric cancer shows positive Phase 3 results
Eli Lilly announced results of the global Phase III trial of ramucirumab - CYRAMZA - in combination with paclitaxel in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma. The addition of ramucirumab to paclitaxel showed a statistically significant improvement in median overall survival, meeting its primary endpoint; it also met secondary endpoints of progression-free survival and objective response rate. Data from the trial were first presented in January. Ramucirumab has now been the focus of two positive Phase III gastric cancer trials that have demonstrated statistically significant improvements in both overall survival and progression-free survival.
08:01 EDTLLYDow AgroSciences announces R&D agreement with Lilly's Elanco
Two Indiana agricultural companies, Elanco, the animal health division of Eli Lilly and Company (LLY), and Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company (DOW), are announcing a strategic research and development agreement that will focus on developing integrated solutions to enable livestock producers to increase meat and milk production to meet the demands of the growing global population.
06:10 EDTLLYFDA panel votes 20-1 to study changes to testosterone therapies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use